Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...
Drug
Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of...
Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer
Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...
Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...
Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing...
Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...
Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors
Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...
Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...
Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines
Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it...
Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard
Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...
Eli Lilly’s Subsidiary Akouos Reports Positive Preliminary Results for Gene Therapy in Hearing Loss
Eli Lilly (NYSE: LLY) has announced preliminary results from a Phase I/II study conducted by...
Biosion’s SIRPα-Targeting Monoclonal Antibody BSI-082 Clears US FDA Clinical Trial Hurdle
Biosion, a global clinical-stage biotechnology company dedicated to developing antibody-based therapies for immune and oncologic...
IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis
China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...
MSD’s Keytruda Combines with PharmAbcine’s PMC-309 in Phase Ia/b Solid Tumor Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda...
China Grand Pharmaceutical Gets NMPA Green Light for mRNA Cancer Vaccine ARC01 Phase I Study
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...
Boan Biotech Secures FDA Orphan Drug Designations for Two Claudin18.2 Targeting Candidates
Boan Biotech (HKG: 6955), a Chinese biotechnology company, has announced that it has received orphan...
Lingyi Biotechnology’s Gene Therapy Candidate LY-M001 Gets FDA Green Light for Gaucher’s Disease
Lingyi Biotechnology Co., Ltd, a China-based gene therapy developer, has secured clinical trial approval from...